We welcome the opportunity to share our passion for our product with partners who have interest in advancing our program with us. Prospective partners may discover us as the “best-kept secret” in the pharmaceutical industry pipeline. Our achievements so far include
- One FDA breakthrough designation,
- Two orphan drug designations, and
- Three United States patents.
We have two active INDs in two therapeutic areas and planning a third IND in another therapeutic area. We are conducting phase 2B studies for the acute treatment of migraine with associated nausea, which is an unmet medical need condition. If supported by the phase 2B clinical trial results, ALLOD-2 could receive a breakthrough designation for episodic migraine with associated nausea. Additionally, the success of the migraine prevention phase 2B study may indicate, ALLOD-2, unlike all other therapeutic options for the acute treatment of migraine, does not cause medication overuse headache (MOH), which is another unmet medical need condition.
We anticipate our product candidate to become phase 3 ready for the indication of the acute treatment of migraine in mid-2018.